Lilly's Foundayo Cuts Cardiovascular Death by 53% in Landmark Diabetes Trial
LLY sits 60% above its 52-week low of $725.31.
Summary
Lilly's oral GLP-1 Foundayo (orforglipron) delivered striking cardiovascular outcomes in the ACHIEVE-4 trial, its largest and longest type 2 diabetes study. The drug showed a 53% lower risk of cardiovascular death and 57% lower all-cause death versus insulin glargine, along with reduced MACE-4 by 16%, MACE-3 by 23%, and improved cardiometabolic health. It also slowed kidney decline with 2.8 mL/min/1.73 m² smaller eGFR reduction and 27.1% greater albuminuria reduction. These results position Foundayo as a potential first-line oral option with hard-outcome benefits, not just glucose control. This follows the FDA approval of Foundayo for obesity and the recent Mounjaro cardiovascular indication, reinforcing Lilly's dominance in cardiometabolic disease. The data could accelerate adoption and support premium pricing, with regulatory submissions for cardiovascular claims likely next. Eli Lilly says Foundayo helped patients lose weight in a Phase 3 trial.
Updated with a Benzinga report · What changed
Updates
· Benzinga — ACHIEVE-4 showed Foundayo reduced MACE-4 by 16%, MACE-3 by 23%, and slowed kidney decline with 2.8 mL/min/1.73 m² smaller eGFR reduction and 27.1% greater albuminuria reduction.
At the time of this announcement, LLY was trading at $1,162.58 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $725.31 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.